标题
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
作者
关键词
-
出版物
Cancers
Volume 12, Issue 2, Pages 407
出版商
MDPI AG
发表日期
2020-02-12
DOI
10.3390/cancers12020407
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Exosome-Transmitted PSMA3 and PSMA3-AS1 Promotes Proteasome Inhibitors Resistance in Multiple Myeloma
- (2019) Hongxia Xu et al. CLINICAL CANCER RESEARCH
- An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers
- (2019) Luciana De Luca et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Recycling therapies for myeloma: The need for prospective trials
- (2019) Shaji K. Kumar CANCER
- Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
- (2019) Joseph Mikhael et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel targets for the treatment of relapsing multiple myeloma
- (2019) Nicola Giuliani et al. Expert Review of Hematology
- Facing lenalidomide-refractory myeloma
- (2019) Michele Cavo BLOOD
- Multiple myeloma: Every year a new standard?
- (2019) S. Vincent Rajkumar HEMATOLOGICAL ONCOLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
- (2019) Benjamin G. Barwick et al. Frontiers in Immunology
- The multi-factorial nature of clinical multidrug resistance in cancer
- (2019) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- Selinexor: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma
- (2019) Minjie Gao et al. JNCI-Journal of the National Cancer Institute
- Responses to selinexor in multiple myeloma
- (2019) Diana Romero Nature Reviews Clinical Oncology
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic landscape and chronological reconstruction of driver events in multiple myeloma
- (2019) Francesco Maura et al. Nature Communications
- Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance
- (2019) M. Helena Vasconcelos et al. DRUG RESISTANCE UPDATES
- An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma
- (2018) Vincent L. Hansen et al. Clinical Lymphoma Myeloma & Leukemia
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
- (2018) Niccolo Bolli et al. LEUKEMIA
- The multiple myelomas — current concepts in cytogenetic classification and therapy
- (2018) Shaji K. Kumar et al. Nature Reviews Clinical Oncology
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
- (2018) Robert A. Kyle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panobinostat and Multiple Myeloma in 2018
- (2018) Andrew J. Yee et al. ONCOLOGIST
- Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management
- (2018) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
- (2018) Robert Z. Orlowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
- (2018) Carolina Marini et al. ANNALS OF HEMATOLOGY
- Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
- (2018) Shaji K. Kumar et al. BLOOD
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
- (2018) Praful Ravi et al. Blood Cancer Journal
- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
- (2017) A Besse et al. LEUKEMIA
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- Epigenetics in multiple myeloma: From mechanisms to therapy
- (2017) Mohammad Alzrigat et al. SEMINARS IN CANCER BIOLOGY
- Which therapies will move to the front line for multiple myeloma?
- (2017) María J Cejalvo et al. Expert Review of Hematology
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells
- (2016) Vanessa Lopes-Rodrigues et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo
- (2016) Vidal Jarauta et al. CANCER LETTERS
- Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
- (2016) JP Laubach et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
- (2016) Cristina P.R. Xavier et al. CURRENT CANCER DRUG TARGETS
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
- (2016) Katarzyna Baranowska et al. Oncotarget
- Multiple myeloma cancer stem cells
- (2016) Minjie Gao et al. Oncotarget
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
- (2015) K. Lagrue et al. BLOOD
- How I treat relapsed myeloma
- (2015) J. Blade et al. BLOOD
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
- (2015) P. G. Richardson et al. BLOOD
- Frontline therapy of multiple myeloma
- (2015) P. Moreau et al. BLOOD
- Smoldering multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- How I treat high-risk myeloma
- (2015) S. Lonial et al. BLOOD
- Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
- (2015) N. W. C. J. van de Donk et al. BLOOD
- Pathogenesis beyond the cancer clone(s) in multiple myeloma
- (2015) G. Bianchi et al. BLOOD
- Global hypomethylation in myeloma is associated with poor prognosis
- (2015) Jonathan I. Sive et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma
- (2015) P. J. Talley et al. BRITISH MEDICAL BULLETIN
- Panobinostat for the Treatment of Multiple Myeloma
- (2015) J. P. Laubach et al. CLINICAL CANCER RESEARCH
- Plasma cell leukemia: from biology to treatment
- (2015) Tomas Jelinek et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms in multiple myeloma drug resistance
- (2015) Nicholas Nikesitch et al. JOURNAL OF CLINICAL PATHOLOGY
- Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
- (2015) S Lonial et al. LEUKEMIA
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
- (2015) Salma Afifi et al. PHARMACOTHERAPY
- Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles
- (2015) Diana Sousa et al. TRENDS IN MOLECULAR MEDICINE
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- (2015) A M Rajan et al. Blood Cancer Journal
- Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
- (2015) Reinaldo Franqui-Machin et al. Oncotarget
- Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
- (2015) Wen-Chi Yang et al. Biomed Research International
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Identify multiple myeloma stem cells: Utopia?
- (2015) Ilaria Saltarella World Journal of Stem Cells
- Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
- (2015) Adil Doganay Duru et al. PLoS One
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
- (2015) Jahangir Abdi et al. Oncotarget
- INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
- (2015) Jun Li et al. NEOPLASIA
- Combined autophagy and proteasome inhibition
- (2014) Dan T Vogl et al. Autophagy
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
- (2014) J. Wang et al. BLOOD
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
- (2014) Nianhang. Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
- (2014) A. Ferrucci et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma
- (2014) Saad Z. Usmani et al. Clinical Lymphoma Myeloma & Leukemia
- Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- (2014) Jae-Sook Ahn et al. Clinical Lymphoma Myeloma & Leukemia
- Cyclin D1 Amplification in Multiple Myeloma Is Associated With Multidrug Resistance Expression
- (2014) Eman M. Sewify et al. Clinical Lymphoma Myeloma & Leukemia
- The potential of miRNAs as biomarkers for multiple myeloma
- (2014) Alberto Rocci et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib
- (2014) M. Gambella et al. HAEMATOLOGICA
- The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy
- (2014) Naohiro Sekiguchi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
- (2014) Lenka Kubiczkova et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
- (2014) O Landgren et al. LEUKEMIA
- Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma
- (2014) Y Yang et al. LEUKEMIA
- The role of P-glycoprotein in drug resistance in multiple myeloma
- (2014) Joseph Abraham et al. LEUKEMIA & LYMPHOMA
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
- (2014) D S Siegel et al. Blood Cancer Journal
- Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
- (2014) B A Walker et al. Blood Cancer Journal
- MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
- (2014) Chonglei Bi et al. Biomed Research International
- Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
- (2013) Teresa S. Hawley et al. AMERICAN JOURNAL OF HEMATOLOGY
- RAR 2 expression confers myeloma stem cell features
- (2013) Y. Yang et al. BLOOD
- The effects of bortezomib on bone disease in patients with multiple myeloma
- (2013) Mohamad Mohty et al. CANCER
- The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
- (2013) Robert O’Connor et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
- (2013) E. Leone et al. CLINICAL CANCER RESEARCH
- Aberrant microRNA expression in multiple myeloma
- (2013) Konstantinos Dimopoulos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma
- (2013) M. Chatterjee et al. HAEMATOLOGICA
- Extracellular vesicles: Exosomes, microvesicles, and friends
- (2013) Graça Raposo et al. JOURNAL OF CELL BIOLOGY
- BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
- (2013) Aldo M. Roccaro et al. JOURNAL OF CLINICAL INVESTIGATION
- Fact or fiction - identifying the elusive multiple myeloma stem cell
- (2013) Joshua Kellner et al. Journal of Hematology & Oncology
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
- (2013) L. Vincenz et al. MOLECULAR CANCER THERAPEUTICS
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- How to select among available options for the treatment of multiple myeloma
- (2012) J. L. Harousseau ANNALS OF ONCOLOGY
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
- (2012) P. L. Bergsagel et al. BLOOD
- Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
- (2012) Z. Tian et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Interleukin-6 signaling pathway in targeted therapy for cancer
- (2012) Yuqi Guo et al. CANCER TREATMENT REVIEWS
- CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
- (2012) Yuan Xiao Zhu et al. LEUKEMIA & LYMPHOMA
- Arsenic Trioxide Exerts Antimyeloma Effects by Inhibiting Activity in the Cytoplasmic Substrates of Histone Deacetylase 6
- (2012) Xiaoyan Qu et al. PLoS One
- miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
- (2012) N Amodio et al. Cell Death & Disease
- Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
- (2012) T Ishii et al. Blood Cancer Journal
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
- (2012) A Kalff et al. Blood Cancer Journal
- Pathogenesis of Myeloma
- (2011) Kenneth C. Anderson et al. Annual Review of Pathology-Mechanisms of Disease
- Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1
- (2011) Yi-Kun Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
- (2011) A. Palumbo et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
- (2011) Sally A. Hunsucker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- (2011) K. D. Boyd et al. CLINICAL CANCER RESEARCH
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- The controversial role of ABC transporters in clinical oncology
- (2011) Akina Tamaki et al. Essays in Biochemistry
- The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
- (2011) Kevin D. Boyd et al. GENES CHROMOSOMES & CANCER
- A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells
- (2011) Li Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
- (2011) Mu Hao et al. Journal of Hematology & Oncology
- The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
- (2011) K A Monaghan et al. LEUKEMIA
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation
- (2011) Xudong Wang et al. LEUKEMIA & LYMPHOMA
- Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
- (2011) T. Khong et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- MicroRNAs: New Players in Multiple Myeloma
- (2011) Flavia Pichiorri et al. Frontiers in Genetics
- MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines
- (2010) Reinhold Munker et al. ACTA HAEMATOLOGICA
- The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
- (2010) F. M. Ross et al. HAEMATOLOGICA
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
- (2010) L. Lode et al. HAEMATOLOGICA
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
- (2010) M A Dimopoulos et al. LEUKEMIA
- Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome
- (2010) Ba Thanh-Truc Ngo et al. LEUKEMIA & LYMPHOMA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
- (2009) Pavel Nemec et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
- (2009) P. Richardson et al. BLOOD
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
- (2009) A. M. Roccaro et al. BLOOD
- The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
- (2009) M. Milani et al. CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of action of lenalidomide in hematological malignancies
- (2009) Venumadhav Kotla et al. Journal of Hematology & Oncology
- Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
- (2009) R. Burger et al. MOLECULAR CANCER THERAPEUTICS
- Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
- (2009) Jean-Luc Harousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
- (2008) Patricia Balsas et al. BIOCHEMICAL PHARMACOLOGY
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- The prognostic significance of 8p21 deletion in multiple myeloma
- (2008) T. Sutlu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer stem cells in multiple myeloma
- (2008) Nilanjan Ghosh et al. CANCER LETTERS
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment
- (2008) A. Huston et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
- (2008) J. L.R. Brito et al. HAEMATOLOGICA
- Clinical and biological significance of RAS mutations in multiple myeloma
- (2008) W J Chng et al. LEUKEMIA
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
- (2008) F. Pichiorri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started